And we believe that we'll have the same flexibility that you typically have in this market around dose titration and other things.

Source: https://seekingalpha.com/article/4625743-revance-therapeutics-inc-rvnc-q2-2023-earnings-call-transcript?source=feed_all_articles

“In an effort to offer patients an effective titration schedule, the bite registration is generally made at the so called maximal comfortable protrusion, minus 2.0 mm after DISE investigation.

Source: https://www.marketscreener.com/quote/stock/PROSOMNUS-INC-147859919/news/Data-Published-by-Cureus-Journal-of-Medical-Science-Shows-Successful-Treatment-of-Obstructive-Sleep-45599278/?utm_medium=RSS&utm_content=20231219

Okay, and so I think we do see increases in Cmax with increasing dose, I think the major factor that's going to affect the rate of somnolence is going to be a titration rate.

Source: https://seekingalpha.com/article/4585468-marinus-pharmaceuticals-inc-mrns-q4-2022-earnings-call-transcript?source=feed_all_articles

We’d point out that we’re the only drug in development for either obesity or NASH that’s incretin-based that can actually dose without dose titration.

Source: https://seekingalpha.com/article/4582972-altimmune-alt-q4-2022-earnings-call-transcript?source=feed_all_articles